Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study

BACKGROUND: Nivolumab combined with chemotherapy has been shown to improve prognosis in patients with untreated, human epidermal growth factor receptor 2 (HER2)-negative advanced gastric cancer (GC) and programmed death ligand-1 (PD-L1) combined positive score (CPS) ≥5. However, the available first-...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Jinyu, Gong, Wenjing, Sun, Ping, Wang, Xuan, Liu, Aina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830341/
https://www.ncbi.nlm.nih.gov/pubmed/36636085
http://dx.doi.org/10.21037/jgo-22-1229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830341/
https://www.ncbi.nlm.nih.gov/pubmed/36636085
http://dx.doi.org/10.21037/jgo-22-1229

Ejemplares similares